编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规...
编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规范地应用...
Medication Adherence to SGLT2 Inhibitors vs. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Meta-Analysisdoi:10.1681/ASN.20245w2bgaw1Whitney SussmanErin R. WeedaConner Elizabeth JohnsonAmerican Society of NephrologyJournal of the American Society of Nephrology...
Second, SGLT2 inhibitors may increase myocardial energy production; alleviate systemic microvascular dysfunction, which is prevalent in both the myocardium and skeletal muscle in HFpEF; improve systemic endothelial function; reduce systemic inflammation and oxidative stress; and improve insulin sensitivity and...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a novel class of oral hypoglycaemic medication, have been demonstrated to potentially reduce the risk of cardiovascular outcomes, especially heart failure (HF) and all-cause mortality, in several large placebo-controlled randomized controlled trials (...
This finding is indeed intriguing given the established role of glycolysis in cancer cell survival. Canagliflozin has additive anti-proliferative efficacy over specific OxPhos inhibitors indicating that this drug engages additional molecular pathways in its anti-proliferative action beyond metabolic stress ...
SGLT2 inhibitors (SGLT2-I) C-aryl glucosides Type 2 diabetes 1. Introduction Diabetes mellitus (DM) is a metabolic condition characterised by high or abnormal blood sugar levels, resulting in long-term damage to the heart, blood vessels, nerves, kidneys, and eyes [1,2]. Diabetes affects pe...
PharmacoEconomics - Open (2025) 9:69–81 https://doi.org/10.1007/s41669-024-00526-2 ORIGINAL RESEARCH ARTICLE Cost‑Utility and Budget Impact Analysis of Adding SGLT‑2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database ...
While incretin modulation has been a popular therapeutic intervention (beyond RAAS modulation) to combat DN, SGLT2 inhibitors have gained acceptance in dual (with metformin) and triple therapy modes (metformin and sulfonylurea) in prevalent anti-type2 diabetic medication (Clar et al., 2012). GLP-...
Foodand Drug Administration; FG: Fournier'sgangrene; GUTI: Genitourinarytract infections; HF: Heartfailure; HFrEF: Heartfailure with reduced ejection fraction; PRR: Proportionalreporting ratios; RCT: Randomizedcontrolled trials; SGLT2i: Sodi- umglucose cotransporter-2 inhibitors; T2D: Type2 diab...